Beltran, H., Danila, D., Montgomery, B., Szmulewitz, R., Vaishampayan, U., Armstrong, A., … Tagawa, S. T. (2016). A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC). Annals of Oncology, 27, vi565. https://doi.org/10.1093/annonc/mdw435.21

Beltran, H., D. Danila, B. Montgomery, R. Szmulewitz, U. Vaishampayan, A. Armstrong, M. Stein, et al. “A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC).” Annals of Oncology 27 (October 1, 2016): vi565. https://doi.org/10.1093/annonc/mdw435.21.

Beltran H, Danila D, Montgomery B, Szmulewitz R, Vaishampayan U, Armstrong A, et al. A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC). Annals of Oncology. 2016 Oct 1;27:vi565.

Beltran, H., et al. “A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC).” Annals of Oncology, vol. 27, Oct. 2016, p. vi565. Scopus, doi:10.1093/annonc/mdw435.21.

Beltran H, Danila D, Montgomery B, Szmulewitz R, Vaishampayan U, Armstrong A, Stein M, Hoimes C, Pinski J, Scher H, Puca L, Bareja R, Wong W, Rubin M, Mosquera JM, Sboner A, Oromendia C, Nanus D, Ballman K, Tagawa ST. A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC). Annals of Oncology. 2016 Oct 1;27:vi565.